{"entity":{"type":"insider","cik":"0001606302","url":"/insider/0001606302","json_url":"/insider/0001606302.json","name":"McMinn Rachel","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":18,"n_filings":18,"first":"2015-07-17","last":"2026-03-30","span_basis":"filed_date"},"name_variants":[{"name":"McMinn Rachel","source":"filing","n_filings":18,"first_seen":"2015-07-17","last_seen":"2026-03-30"}],"transactions":[{"id":6076703,"accession":"0001606302-26-000005","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001606302-26-000005","line_url":"/filing/0001606302-26-000005#line-1","is_derivative":false,"issuer_cik":"0001404644","issuer_name":"Neurogene Inc.","issuer_ticker":"NGNE","issuer_name_source":null,"issuer_url":"/issuer/0001404644","owner_cik":"0001606302","owner_name":"McMinn Rachel","owner_display_name":"McMinn Rachel","owner_url":"/insider/0001606302","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3352.0,"shares_display":"3,352","price_per_share":22.0749,"price_display":"22.07","price_state":"stated","total_value":73995.0648,"total_display":"73,995.06","total_whole":"73,995","shares_owned_after":1344307.0,"shares_owned_after_display":"1,344,307","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-26","filed_date":"2026-03-30","scope":"insider"},{"id":2188191,"accession":"0001404644-24-000112","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001404644-24-000112","line_url":"/filing/0001404644-24-000112#line-1","is_derivative":false,"issuer_cik":"0001404644","issuer_name":"Neurogene Inc.","issuer_ticker":"NGNE","issuer_name_source":null,"issuer_url":"/issuer/0001404644","owner_cik":"0001606302","owner_name":"McMinn Rachel","owner_display_name":"McMinn Rachel","owner_url":"/insider/0001606302","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":47500.0,"shares_display":"47,500","price_per_share":20.4,"price_display":"20.40","price_state":"stated","total_value":969000.0,"total_display":"969,000.00","total_whole":"969,000","shares_owned_after":1297859.0,"shares_owned_after_display":"1,297,859","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-22","filed_date":"2024-11-25","scope":"insider"},{"id":4996590,"accession":"0001144204-17-051412","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-17-051412","line_url":"/filing/0001144204-17-051412#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001606302","owner_name":"McMinn Rachel","owner_display_name":"McMinn Rachel","owner_url":"/insider/0001606302","role":"Officer (Chief Strategy Officer)","role_mark":"O","role_mark_label":"Officer (Chief Strategy Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Strategy Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":283.0,"shares_display":"283","price_per_share":58.8932,"price_display":"58.89","price_state":"stated","total_value":16666.7756,"total_display":"16,666.78","total_whole":"16,667","shares_owned_after":16875.0,"shares_owned_after_display":"16,875","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-10-02","filed_date":"2017-10-04","scope":"insider"},{"id":4617276,"accession":"0001144204-17-040071","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-17-040071","line_url":"/filing/0001144204-17-040071#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001606302","owner_name":"McMinn Rachel","owner_display_name":"McMinn Rachel","owner_url":"/insider/0001606302","role":"Officer (Chief Strategy Officer)","role_mark":"O","role_mark_label":"Officer (Chief Strategy Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Strategy Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":130.0,"shares_display":"130","price_per_share":123.1176,"price_display":"123.12","price_state":"stated","total_value":16005.288,"total_display":"16,005.29","total_whole":"16,005","shares_owned_after":17158.0,"shares_owned_after_display":"17,158","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-07-31","filed_date":"2017-08-02","scope":"insider"},{"id":4316118,"accession":"0001144204-17-035810","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-17-035810","line_url":"/filing/0001144204-17-035810#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001606302","owner_name":"McMinn Rachel","owner_display_name":"McMinn Rachel","owner_url":"/insider/0001606302","role":"Officer (Chief Strategy Officer)","role_mark":"O","role_mark_label":"Officer (Chief Strategy Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Strategy Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":257.0,"shares_display":"257","price_per_share":121.78,"price_display":"121.78","price_state":"stated","total_value":31297.46,"total_display":"31,297.46","total_whole":"31,297","shares_owned_after":17288.0,"shares_owned_after_display":"17,288","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-07-03","filed_date":"2017-07-05","scope":"insider"},{"id":4373137,"accession":"0001144204-17-024325","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-17-024325","line_url":"/filing/0001144204-17-024325#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001606302","owner_name":"McMinn Rachel","owner_display_name":"McMinn Rachel","owner_url":"/insider/0001606302","role":"Officer (Chief Strategy Officer)","role_mark":"O","role_mark_label":"Officer (Chief Strategy Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Strategy Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":114.0,"shares_display":"114","price_per_share":113.1201,"price_display":"113.12","price_state":"stated","total_value":12895.6914,"total_display":"12,895.69","total_whole":"12,896","shares_owned_after":17545.0,"shares_owned_after_display":"17,545","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-05-01","filed_date":"2017-05-03","scope":"insider"},{"id":5224494,"accession":"0001144204-17-019297","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-17-019297","line_url":"/filing/0001144204-17-019297#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001606302","owner_name":"McMinn Rachel","owner_display_name":"McMinn Rachel","owner_url":"/insider/0001606302","role":"Officer (Chief Strategy Officer)","role_mark":"O","role_mark_label":"Officer (Chief Strategy Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Strategy Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":257.0,"shares_display":"257","price_per_share":114.9973,"price_display":"115.00","price_state":"stated","total_value":29554.3061,"total_display":"29,554.31","total_whole":"29,554","shares_owned_after":17659.0,"shares_owned_after_display":"17,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-04-03","filed_date":"2017-04-05","scope":"insider"},{"id":4173507,"accession":"0001144204-17-000938","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-17-000938","line_url":"/filing/0001144204-17-000938#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001606302","owner_name":"McMinn Rachel","owner_display_name":"McMinn Rachel","owner_url":"/insider/0001606302","role":"Officer (Chief Strategy Officer)","role_mark":"O","role_mark_label":"Officer (Chief Strategy Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Strategy Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":816.0,"shares_display":"816","price_per_share":103.9191,"price_display":"103.92","price_state":"stated","total_value":84797.9856,"total_display":"84,797.99","total_whole":"84,798","shares_owned_after":12916.0,"shares_owned_after_display":"12,916","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-01-03","filed_date":"2017-01-05","scope":"insider"},{"id":2173113,"accession":"0001144204-16-131218","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-16-131218","line_url":"/filing/0001144204-16-131218#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001606302","owner_name":"McMinn Rachel","owner_display_name":"McMinn Rachel","owner_url":"/insider/0001606302","role":"Officer (Chief Strategy Officer)","role_mark":"O","role_mark_label":"Officer (Chief Strategy Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Strategy Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":129.0,"shares_display":"129","price_per_share":123.8165,"price_display":"123.82","price_state":"stated","total_value":15972.3285,"total_display":"15,972.33","total_whole":"15,972","shares_owned_after":13732.0,"shares_owned_after_display":"13,732","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-10-31","filed_date":"2016-11-02","scope":"insider"},{"id":2966816,"accession":"0001144204-16-116059","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-16-116059","line_url":"/filing/0001144204-16-116059#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001606302","owner_name":"McMinn Rachel","owner_display_name":"McMinn Rachel","owner_url":"/insider/0001606302","role":"Officer (Chief Strategy Officer)","role_mark":"O","role_mark_label":"Officer (Chief Strategy Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Strategy Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":125.0,"shares_display":"125","price_per_share":176.565,"price_display":"176.56","price_state":"stated","total_value":22070.625,"total_display":"22,070.62","total_whole":"22,071","shares_owned_after":13861.0,"shares_owned_after_display":"13,861","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-08-01","filed_date":"2016-08-02","scope":"insider"},{"id":2451074,"accession":"0001144204-16-112098","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-16-112098","line_url":"/filing/0001144204-16-112098#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001606302","owner_name":"McMinn Rachel","owner_display_name":"McMinn Rachel","owner_url":"/insider/0001606302","role":"Officer (Chief Strategy Officer)","role_mark":"O","role_mark_label":"Officer (Chief Strategy Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Strategy Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":106.0,"shares_display":"106","price_per_share":145.1092,"price_display":"145.11","price_state":"stated","total_value":15381.5752,"total_display":"15,381.58","total_whole":"15,382","shares_owned_after":13986.0,"shares_owned_after_display":"13,986","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-07-05","filed_date":"2016-07-07","scope":"insider"},{"id":2089834,"accession":"0001144204-16-099043","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-16-099043","line_url":"/filing/0001144204-16-099043#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001606302","owner_name":"McMinn Rachel","owner_display_name":"McMinn Rachel","owner_url":"/insider/0001606302","role":"Officer (Chief Strategy Officer)","role_mark":"O","role_mark_label":"Officer (Chief Strategy Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Strategy Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":130.0,"shares_display":"130","price_per_share":147.4901,"price_display":"147.49","price_state":"stated","total_value":19173.713,"total_display":"19,173.71","total_whole":"19,174","shares_owned_after":14087.0,"shares_owned_after_display":"14,087","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-05-02","filed_date":"2016-05-04","scope":"insider"},{"id":3332625,"accession":"0001144204-16-093111","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-16-093111","line_url":"/filing/0001144204-16-093111#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001606302","owner_name":"McMinn Rachel","owner_display_name":"McMinn Rachel","owner_url":"/insider/0001606302","role":"Officer (Chief Strategy Officer)","role_mark":"O","role_mark_label":"Officer (Chief Strategy Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Strategy Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":104.0,"shares_display":"104","price_per_share":130.76,"price_display":"130.76","price_state":"stated","total_value":13599.04,"total_display":"13,599.04","total_whole":"13,599","shares_owned_after":14217.0,"shares_owned_after_display":"14,217","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-04-04","filed_date":"2016-04-06","scope":"insider"},{"id":2565487,"accession":"0001144204-16-078888","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-16-078888","line_url":"/filing/0001144204-16-078888#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001606302","owner_name":"McMinn Rachel","owner_display_name":"McMinn Rachel","owner_url":"/insider/0001606302","role":"Officer (Chief Strategy Officer)","role_mark":"O","role_mark_label":"Officer (Chief Strategy Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Strategy Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":128.0,"shares_display":"128","price_per_share":103.5609,"price_display":"103.56","price_state":"stated","total_value":13255.7952,"total_display":"13,255.80","total_whole":"13,256","shares_owned_after":7621.0,"shares_owned_after_display":"7,621","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-02-01","filed_date":"2016-02-03","scope":"insider"},{"id":2745467,"accession":"0001144204-16-074240","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-16-074240","line_url":"/filing/0001144204-16-074240#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001606302","owner_name":"McMinn Rachel","owner_display_name":"McMinn Rachel","owner_url":"/insider/0001606302","role":"Officer (Chief Strategy Officer)","role_mark":"O","role_mark_label":"Officer (Chief Strategy Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Strategy Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":469.0,"shares_display":"469","price_per_share":145.9037,"price_display":"145.90","price_state":"stated","total_value":68428.8353,"total_display":"68,428.84","total_whole":"68,429","shares_owned_after":7749.0,"shares_owned_after_display":"7,749","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-01-04","filed_date":"2016-01-05","scope":"insider"},{"id":8701400,"accession":"0001144204-15-062870","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-15-062870","line_url":"/filing/0001144204-15-062870#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001606302","owner_name":"McMinn Rachel","owner_display_name":"McMinn Rachel","owner_url":"/insider/0001606302","role":"Officer (Chief Strategy Officer)","role_mark":"O","role_mark_label":"Officer (Chief Strategy Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Strategy Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":125.0,"shares_display":"125","price_per_share":160.2352,"price_display":"160.24","price_state":"stated","total_value":20029.4,"total_display":"20,029.40","total_whole":"20,029","shares_owned_after":8218.0,"shares_owned_after_display":"8,218","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-11-02","filed_date":"2015-11-04","scope":"insider"},{"id":8071550,"accession":"0001144204-15-046298","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-15-046298","line_url":"/filing/0001144204-15-046298#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001606302","owner_name":"McMinn Rachel","owner_display_name":"McMinn Rachel","owner_url":"/insider/0001606302","role":"Officer (Chief Strategy Officer)","role_mark":"O","role_mark_label":"Officer (Chief Strategy Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Strategy Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":127.0,"shares_display":"127","price_per_share":262.0927,"price_display":"262.09","price_state":"stated","total_value":33285.7729,"total_display":"33,285.77","total_whole":"33,286","shares_owned_after":4293.0,"shares_owned_after_display":"4,293","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-07-31","filed_date":"2015-08-04","scope":"insider"},{"id":8673524,"accession":"0001144204-15-043174","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-15-043174","line_url":"/filing/0001144204-15-043174#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001606302","owner_name":"McMinn Rachel","owner_display_name":"McMinn Rachel","owner_url":"/insider/0001606302","role":"Officer (Chief Strategy Officer)","role_mark":"O","role_mark_label":"Officer (Chief Strategy Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Strategy Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":503.0,"shares_display":"503","price_per_share":255.1236,"price_display":"255.12","price_state":"stated","total_value":128327.1708,"total_display":"128,327.17","total_whole":"128,327","shares_owned_after":4420.0,"shares_owned_after_display":"4,420","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-05-01","filed_date":"2015-07-17","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":18,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":17,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":18},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001404644","name":"Neurogene Inc.","url":"/issuer/0001404644","role":"Director, Officer (Chief Executive Officer)","n_filings":2,"first_seen":"2024-11-25","last_seen":"2026-03-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001270073","name":"INTERCEPT PHARMACEUTICALS INC","url":"/issuer/0001270073","role":"Officer (Chief Strategy Officer)","n_filings":16,"first_seen":"2015-07-17","last_seen":"2017-10-04"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001606302","retrieved_at":"2026-08-23T18:50:40+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}